Azopt®
Brinzolamide 1% · ophthalmic suspension
Antiglaucoma
Approved uses
Elevated IOP in open-angle glaucoma or ocular hypertension
1 drop in the affected eye(s) TID
Lowers IOP 4.2 to 5.6 mmHg across peak and trough, matching dorzolamide with less stinging.
OFF-LABELNot in the FDA label for this product
Cystoid macular edema in inherited retinal dystrophy
1 drop TID
Case series · n=7
Weak, case-series level. Retrospective single-center chart review of 7 children (4 X-linked retinoschisis, 2 retinitis pigmentosa, 1 Leber congenital amaurosis), all prescribed TID, 6 treated: 4 of 6 showed a mild decrease in central macular thickness and all 6 had improved acuity at a mean 33 months, and the authors state that further study is needed. The larger carbonic anhydrase inhibitor evidence base in this setting was built on topical dorzolamide and oral acetazolamide, not on brinzolamide.
Contraindications
Hypersensitivity to any component of this product.
1% (brinzolamide 10 mg/mL) ophthalmic suspension, 10 mL, 15 mL
Topical carbonic anhydrase II inhibitor. Inhibiting the enzyme in the ciliary processes decreases aqueous humor secretion, presumably by slowing bicarbonate ion formation with subsequent reduction in sodium and fluid transport, so IOP falls.
Warnings & Precautions
- Sulfonamide hypersensitivity: AZOPT is a sulfonamide and is absorbed systemically, so the same types of adverse reactions attributable to sulfonamides may occur. Sensitization may recur when a sulfonamide is readministered by any route; stop immediately if signs of serious reactions or hypersensitivity occur.
- Severe reactions to sulfonamides: Fatalities have occurred, although rarely, due to severe reactions to sulfonamides, including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias.
- Corneal edema: Carbonic anhydrase activity has been observed in the corneal endothelium, and there is an increased potential for developing corneal edema in patients with low endothelial cell counts; use caution when prescribing to this group.
- Severe renal impairment: Not studied at CrCl below 30 mL/min and not recommended there, since parent drug and metabolite are excreted predominantly by the kidney.
- Acute angle-closure glaucoma: Not studied in this setting, which needs therapeutic intervention beyond an ocular hypotensive agent.
- Additive systemic effects: Concomitant use with oral carbonic anhydrase inhibitors is not recommended; there is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition.
- Acid-base alterations: Carbonic anhydrase inhibitors may produce acid-base and electrolyte alterations. These were not reported in the brinzolamide trials, but in patients treated with oral carbonic anhydrase inhibitors, rare instances of acid-base alterations have occurred with high-dose salicylate therapy; consider the potential for such drug interactions.
- Transient blurred vision: Vision may blur after dosing, which matters for driving and machinery.
- Contact lens wear: The benzalkonium chloride preservative may be absorbed by soft lenses; remove lenses during instillation, and they may be reinserted 15 minutes after.
- Risk of contamination: Avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, or other surfaces, since the product can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Common Side Effects
The most frequently reported adverse reactions, in 5% to 10% of patients, were blurred vision and bitter, sour, or unusual taste. Adverse reactions occurring in 1% to 5% of patients were blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus, and rhinitis. Reactions reported at an incidence below 1% included allergic reactions, conjunctivitis, diplopia, dizziness, dry mouth, dyspnea, keratopathy, nausea, and urticaria. In postapproval use, serious skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis may occur due to the sulfonamide component.
Pregnancy: No adequate and well-controlled studies in pregnant women. Oral dosing in rats produced decreased fetal body weight with reduced skeletal ossification at 375 times the recommended human ophthalmic dose, no-effect level 125 times; no treatment-related fetal effects at any dose in rabbits.
Lactation: No data on presence in human milk, effects on the breastfed infant, or effects on milk production; detected in the milk of lactating rats.
In a 3-month controlled study in which AZOPT was dosed only twice a day in pediatric patients 4 weeks to 5 years of age, IOP-lowering efficacy was not demonstrated. Five out of 32 patients demonstrated an increase in corneal diameter of one millimeter.